NCT05216887View on ClinicalTrials.gov

A Study to Assess the Pharmacokinetic (PK) Comparability of 2 Fixed Subcutaneous (SC) Doses of Aducanumab (BIIB037) With a Single, Weight-Based Intravenous (IV) Dose in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

123

Participants

Timeline

Start Date

February 1, 2022

Primary Completion Date

July 27, 2022

Study Completion Date

July 27, 2022

Conditions
Healthy Volunteer
Interventions
BIOLOGICAL

Aducanumab

Administered as specified in the treatment arm.

Trial Locations (3)

33143

QPS-MRA, Miami

65802

QPS Missouri, Springfield

92801

Anaheim Clinical Trials, Anaheim

Sponsors

Lead Sponsor

Biogen
All Listed Sponsors
lead

Biogen

INDUSTRY

NCT05216887 - A Study to Assess the Pharmacokinetic (PK) Comparability of 2 Fixed Subcutaneous (SC) Doses of Aducanumab (BIIB037) With a Single, Weight-Based Intravenous (IV) Dose in Healthy Volunteers | Biotech Hunter | Biotech Hunter